Efficacy and safety cebranopadol, a first-in-class, dual NMR agonist in patients with pain due to diabetic peripheral neuropathy (NeuPSIG 2025) - May 27, 2025 - Abstract #GUI-0609-012; Pres time: Sep 6, 2025; 08:30 AM - 06:00 PM; Location: Exhibition & Poster Area; "This study evaluates the analgesic efficacy and safety of once-daily oral cebranopadol at different doses compared to placebo and pregabalin in patients with moderate to severe chronic pain due to DPN. This was a randomized, multi-site, double-blind, placebo- and active-controlled, parallel-group, dose-ranging Phase 2 trial. Cebranopadol demonstrated clinically meaningful analgesic efficacy in patients with painful DPN. Cebranopadol's mechanism of action as a dual-NMR agonist highlights its potential as a promising potential treatment option for neuropathic pain. Additional studies with longer treatment durations and personalized titration protocols are warranted to maximize the therapeutic benefits of cebranopadol while minimizing adverse effects."
Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Peripheral Neuropathic Pain
|
|
Joseph Grieco1; Marc Lesnick1; James Hackworth1
|